Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia
Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia
Active, not recruiting · NCT04712851 · Registry updated 2026-10-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Urogenital Diseases, cervix disorder, dysplasia of cervix, female reproductive system disorder, neoplasm, precancerous condition, uterine disorder | Active, not recruiting | Phase 2 | 2026-10-06 | NCT04712851 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Jonsson Comprehensive Cancer Center | 115 |
| Merck Sharp & Dohme LLC | 650 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of California at Los Angeles / Jonsson Comprehensive Cancer Center | Los Angeles | United States | 2 |